SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
A woman wearing a mask walks by Gilead Sciences headquarters sign in Foster City, California on April 30, 2020. (Photo: Josh Edelson/AFP via Getty Images)
'Absolute Robbery': Gilead Announces $3,120 Price Tag for Covid-19 Drug Developed With $70 Million in Taxpayer Support
"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic. Beyond disgusting," said Sen. Bernie Sanders.
Jun 29, 2020
Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.
"Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
--Peter Maybarduk, Public Citizen
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, called Gilead's pricing--which works out to around $520 per dose for non-government buyers like hospitals--"an offensive display of hubris and disregard for the public" and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all.
Maybarduk pointed to Institute for Clinical and Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.
"Gilead has priced at several thousand dollars a drug that should be in the public domain. For $1 per day, remdesivir can be manufactured at scale with a reasonable profit," Maybarduk said in a statement. "Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
Public Citizen estimated in a May report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir.
Shortly after Gilead's announcement, the U.S. Health and Human Services Department said it reached an agreement with the pharmaceutical giant to purchase more than 500,000 treatment courses of remdesivir for American hospitals.
The Wall Street Journal reported that the United States is "the only developed country where Gilead will charge two prices"--one for government buyers ($390 per dose) and one for non-government buyers like hospitals ($520 per dose). The typical remdesivir treatment course consists of around six doses.
"Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
--Rep. Lloyd Doggett
Unlike the U.S., the Journal notes, the governments of other advanced nations "negotiate drug prices directly with drugmakers."
Rep. Lloyd Doggett (D-Texas), chair of the House Ways and Means Health Subcommittee, said in a statement that "Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
Doggett said he is pressuring the Trump administration and Gilead to disclose the details of their agreement, including the sum the government paid for the 500,000 treatment courses of remdesivir.
On Twitter, Sen. Bernie Sanders (I-Vt.) condemned Gilead's price-tag as "beyond disgusting."
"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic," said Sanders. "Coronavirus treatment must be free to all."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.
"Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
--Peter Maybarduk, Public Citizen
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, called Gilead's pricing--which works out to around $520 per dose for non-government buyers like hospitals--"an offensive display of hubris and disregard for the public" and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all.
Maybarduk pointed to Institute for Clinical and Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.
"Gilead has priced at several thousand dollars a drug that should be in the public domain. For $1 per day, remdesivir can be manufactured at scale with a reasonable profit," Maybarduk said in a statement. "Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
Public Citizen estimated in a May report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir.
Shortly after Gilead's announcement, the U.S. Health and Human Services Department said it reached an agreement with the pharmaceutical giant to purchase more than 500,000 treatment courses of remdesivir for American hospitals.
The Wall Street Journal reported that the United States is "the only developed country where Gilead will charge two prices"--one for government buyers ($390 per dose) and one for non-government buyers like hospitals ($520 per dose). The typical remdesivir treatment course consists of around six doses.
"Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
--Rep. Lloyd Doggett
Unlike the U.S., the Journal notes, the governments of other advanced nations "negotiate drug prices directly with drugmakers."
Rep. Lloyd Doggett (D-Texas), chair of the House Ways and Means Health Subcommittee, said in a statement that "Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
Doggett said he is pressuring the Trump administration and Gilead to disclose the details of their agreement, including the sum the government paid for the 500,000 treatment courses of remdesivir.
On Twitter, Sen. Bernie Sanders (I-Vt.) condemned Gilead's price-tag as "beyond disgusting."
"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic," said Sanders. "Coronavirus treatment must be free to all."
Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.
"Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
--Peter Maybarduk, Public Citizen
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, called Gilead's pricing--which works out to around $520 per dose for non-government buyers like hospitals--"an offensive display of hubris and disregard for the public" and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all.
Maybarduk pointed to Institute for Clinical and Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.
"Gilead has priced at several thousand dollars a drug that should be in the public domain. For $1 per day, remdesivir can be manufactured at scale with a reasonable profit," Maybarduk said in a statement. "Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
Public Citizen estimated in a May report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir.
Shortly after Gilead's announcement, the U.S. Health and Human Services Department said it reached an agreement with the pharmaceutical giant to purchase more than 500,000 treatment courses of remdesivir for American hospitals.
The Wall Street Journal reported that the United States is "the only developed country where Gilead will charge two prices"--one for government buyers ($390 per dose) and one for non-government buyers like hospitals ($520 per dose). The typical remdesivir treatment course consists of around six doses.
"Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
--Rep. Lloyd Doggett
Unlike the U.S., the Journal notes, the governments of other advanced nations "negotiate drug prices directly with drugmakers."
Rep. Lloyd Doggett (D-Texas), chair of the House Ways and Means Health Subcommittee, said in a statement that "Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
Doggett said he is pressuring the Trump administration and Gilead to disclose the details of their agreement, including the sum the government paid for the 500,000 treatment courses of remdesivir.
On Twitter, Sen. Bernie Sanders (I-Vt.) condemned Gilead's price-tag as "beyond disgusting."
"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic," said Sanders. "Coronavirus treatment must be free to all."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.